Gujarat Kidney And Super Speciality Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹1.5(1.32%)
Premium (ELP)
The Initial Public Offering of Gujarat Kidney And Super Speciality Limited's culminated in its successful listing on Dec 30, 2025 at the NSE, BSE trading platform. The company secured 2,20,00,000 Shares through this capital market exercise, with 2,20,00,000 Shares allocated to new capital formation.
Investors participated within the price parameters of ₹108 to ₹114, with minimum investment requirements of 128 shares. The subscription period from Dec 22, 2025 to Dec 24, 2025 witnessed active investor engagement across categories.
Following the subscription closure, share allotment was processed on Dec 26, 2025. The subsequent listing established a public market for the company's shares, enabling price discovery and secondary market trading for investors.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Gujarat Kidney and Super Speciality Limited, incorporated in 2019, provides multispeciality healthcare services across Gujarat through a network of seven hospitals and four pharmacies, offering secondary and tertiary care. The company operates a total bed capacity of 490 beds, with 455 approved and 340 operational, across facilities in Vadodara, Godhra, Bharuch, Borsad, and Anand. Its services cover general and surgical treatments as well as super speciality procedures, including internal medicine, general and minimally invasive surgery, orthopaedics and trauma care, joint replacement, obstetrics and gynaecology, respiratory care, cardiology, diabetology, and anaesthesiology. As of June 30, 2025, the company’s operations are supported by 89 doctors, 332 nurses, and 338 other staff members.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Strong Specialisation in Renal Care – Well-established expertise in renal sciences with advanced sub-specialities, supported by multispeciality hospitals delivering tertiary healthcare services.
- Asset-Light Hospital Operating Model – Hospitals are run through leased and majority-owned entities, allowing expansion with lower capital investment in land and infrastructure.
- Ability to Attract and Retain Medical Professionals – Low attrition among doctors and nurses reflects success in building a stable, skilled workforce through a high-volume, multidisciplinary care approach.
- Risk in Acquisition of Parekhs Hospital – Any difficulty in completing the planned 100% acquisition using issue proceeds may disrupt future growth plans and operational strategy.
- Funding Risk for Ashwini Medical Centre Acquisition – Delays in raising funds for part-payment of the already acquired Ashwini Medical Centre may affect timely settlement with sellers.
- Execution Risks in New Hospital Expansion – Setting up the proposed women’s healthcare hospital in Vadodara faces approval delays, equipment procurement challenges, cost escalation, and lease-related risks that may impact expansion timelines and financial performance.
- Dr. Pragnesh Yashwantsinh Bharpoda
- Dr. Bhartiben Pragnesh Bharpoda
- Dr. Yashwantsingh Motisinh Bharpoda
- Anitaben Yashwantsinh Bharpoda
Gujarat Kidney And Super Speciality Limited
Link Intime India Private Limited